CDTI Innovación, through Innvierte, has completed an investment in this company together with INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR, S.A., with a total amount of €3,600,000. Through this participation, CDTI Innovación contributes to the development of a precision nanotherapy technology platform aimed at advancing new, safer, and more effective anticancer drugs that improve patients’ quality of life.
Nanoligent is a biotechnology company developing targeted cancer therapies using proteins organized in nanoparticles and conjugated with cytotoxic drugs.
The main goal of the company, led by Dr. Montserrat Cano and Dr. Manuel Rodríguez Mariscal, is to develop new anticancer drugs focused especially on aggressive tumors, using an innovative technological platform based on protein–drug nanoconjugates.
These protein–drug nanoparticles act precisely on cancer cells, ensuring that the drug reaches its target with high accuracy. Using specific ligands, the drug is released exclusively at its site of action. Unlike traditional therapies, Nanoligent’s protein architecture remains highly stable after administration, preventing drug activity during systemic circulation and concentrating its effect on specific sites. In addition, the human-origin peptide sequence helps prevent undesired immune responses, further enhancing the safety and efficacy of Nanoligent’s treatments.
This innovative approach is key to precision oncology, offering a high therapeutic index while minimizing side effects.
Founded as a spin-off from the Universitat Autònoma de Barcelona (UAB) and the Institut de Recerca of Hospital de la Santa Creu i Sant Pau, Nanoligent’s mission is to reduce systemic toxicity while improving treatment efficacy.
INVEREADY ASSET MANAGEMENT, S.G.E.I.C., S.A. is a leading financial services firm specialized in alternative assets, wealth management, and traditional investment funds, including INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR, S.A. Founded in 2008 as a venture capital firm, Inveready has evolved into one of the most active investment firms in Spain’s small and medium-sized enterprise segment, currently managing more than €2.2 billion.
The group organizes its services around three main business lines:
With 60 employees, Inveready is headquartered in San Sebastián and has offices in Barcelona and Madrid. It has been recognized as Best Venture Capital Firm in 2017 by SpainCap and Best European Venture Debt Fund in 2023 by Preqin, among other distinctions.
Innvierte is an initiative aimed at promoting business innovation by supporting venture capital investment in technology-based or innovative companies. The program operates through the closed-end investment company Innvierte Economía Sostenible SICC S.M.E., S.A., self-managed and supervised by the Spanish National Securities Market Commission (CNMV), with CDTI Innovación as its sole shareholder.
To date, CDTI Innovación has committed €2.847 billion to 63 investment vehicles that have invested in more than 632 companies, and directly co-invested €726 million in 191 companies.
Innvierte forms part of the Spanish Science, Technology and Innovation Strategy 2021–2027, approved by the Council of Ministers in September 2020. This strategy defines the objectives, reforms, and measures to be adopted across the R&D&I ecosystem to boost its growth and impact, and serves as one of the pillars guiding the Government’s R&D&I policy for the coming years.
The Centre for Technological Development and Innovation (CDTI E.P.E.) is the innovation agency of the Ministry of Science, Innovation and Universities, whose mission is to promote technological innovation in the business sector. CDTI’s goal is to ensure that Spanish companies generate and transform scientific and technical knowledge into globally competitive, sustainable, and inclusive growth.
In 2024, under its new strategic plan, CDTI provided over €2.3 billion in support to Spanish companies and start-ups.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
